BCOR 14.02 Blucora Inc $BCOR Hit a 52 week low of 13.40

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:08 AM

BCOR 14.02 Blucora Inc $BCOR Hit a 52 week low of 13.40 Closing the day 10:45 at 14.02 +0.41 +3.01% With a day low of 13.40 and a total volume of 211,677.

BCOR Recent Posts: http://investorshangout.com/Blucora-Inc-BCOR-54467/

BCOR Blucora Inc Recent Headline News

Activist Fund Targets Ebix to Boost Board Oversight and Unlock Value
at The Street - Mon Nov 17, 5:10AM CST
Barington Capital sent Ebix a letter to call for improved board oversight. Could this be the catalyst the market needs to realize Ebix's value?
SAFT: 60.10 (+0.15), RF: 10.02 (-0.05), CSGS: 25.33 (+0.17), AON: 90.55 (+0.16), EPIQ: 15.81 (+0.12), LRN: 12.20 (+0.10), DRI: 55.99 (+0.38), DDS: 113.63 (+2.87), LOGM: 50.08 (-0.06), WSH: 42.39 (-0.07), EBIX: 16.02 (+0.07), TRAK: 45.55 (+0.51), SCOR: 43.10 (+0.13), BCOR: 14.00 (+0.39), NAVG: 71.31 (+1.45), UVE: 18.72 (+0.49)

Blucora's (BCOR) CEO William Ruckelshaus on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:01PM CST

BCOR: 14.00 (+0.39)

Blucora reports 3Q loss
Automated Insights - Wed Nov 05, 6:24PM CST
BELLEVUE, Wash. (AP) _ Blucora Inc. (BCOR) on Wednesday reported a loss of $2.2 million in its third quarter.
BCOR: 14.00 (+0.39)

Blucora (BCOR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:55PM CST

BCOR: 14.00 (+0.39)

Blucora beats by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:34PM CST

BCOR: 14.00 (+0.39)

Blucora Reports Third Quarter Results
Marketwired - Wed Nov 05, 3:25PM CST
Blucora, Inc. (NASDAQ: BCOR) today announced financial results for the third quarter ended September 30, 2014.
BCOR: 14.00 (+0.39)

Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:35PM CST

CXO: 118.63 (+3.47), CODI: 16.63 (-0.02), EXXI: 7.11 (+0.30), JCOM: 55.60 (-0.39), ATSG: 7.95 (+0.07), GPOR: 53.39 (+1.87), ENS: 60.41 (+0.11), ECYT: 6.35 (+0.05), ALNY: 88.93 (-0.64), KGC: 2.78 (+0.04), GSM: 17.11 (+0.08), BKD: 35.06 (+0.40), DK: 31.68 (-0.08), AR: 53.25 (+0.95), IL: 10.54 (+0.07), DVR: 0.14 (-0.08), IO: 2.73 (+0.13), DEPO: 15.20 (+0.01), ETE: 62.85 (-1.05), AVG: 19.27 (+0.04), CSOD: 30.34 (+0.50), GNW: 9.25 (+0.12), ECOL: 39.23 (-0.03), BWC: 30.05 (+0.01), CPE: 6.20 (+0.31), FNV: 53.58 (+0.39), CTL: 40.53 (-0.59), ASH: 112.56 (-0.28), ENSG: 38.94 (+0.34), CLR: 54.71 (+1.85), ACAS: 14.90 (+0.03), G: 17.80 (+0.08), BREW: 13.73 (+0.02), AWK: 52.30 (-0.13), CVG: 20.74 (+0.09), AREX: 10.97 (+0.35), HTCH: 3.50 (+0.04), ETP: 67.45 (-0.30), ABTL: 10.79 (+0.21), FMI: 23.91 (-0.23), DPM: 52.93 (+0.67), BCOR: 14.00 (+0.39), CDE: 4.36 (+0.11), DRYS: 1.43 (unch), KW: 25.60 (+0.04), BALT: 3.39 (+0.16), ATO: 52.83 (-0.31), EXAR: 8.62 (+0.01), ACLS: 2.13 (-0.02), INWK: 7.36 (+0.08), ALSK: 1.30 (-0.01), CF: 272.89 (+0.86), EFC: 21.79 (-0.01), BIOS: 5.86 (+0.06), DYN: 33.83 (+0.25), DATA: 79.99 (-0.24), ANDE: 56.55 (+0.85), HOLX: 26.23 (-0.06), CBS: 53.57 (+0.23)

Motiwala Capital Q3 Review Letter
Adib Motiwala - at Seeking Alpha - Thu Oct 30, 5:35AM CDT

HES: 83.18 (+0.81), CTCM: 5.86 (-0.06), QCOM: 70.26 (-0.21), NADL: 3.25 (+0.09), BCOR: 14.00 (+0.39), VOD: 35.62 (-0.07), ORCL: 40.96 (+0.04), OUTR: 64.08 (+1.34)

Blucora to Announce Third Quarter Financial Results on November 5, 2014
Marketwired - Wed Oct 29, 5:15PM CDT
Blucora, Inc. (NASDAQ: BCOR) will announce its third quarter 2014 financial results on Wednesday, November 5, 2014, after market close.
BCOR: 14.00 (+0.39)

TaxACT Empowers Small Business Owners to Confidently Take Charge of Their Taxes
Marketwired - Thu Oct 16, 9:25AM CDT
TaxACT(R), the critically acclaimed leader of affordable tax preparation solutions, has released its digital and download products for 2014 small business tax returns.
BCOR: 14.00 (+0.39)

TaxACT 2014 Gives Professional Tax Preparers a Running Start to Tax Season
Marketwire - Tue Oct 07, 9:43AM CDT
TaxACT(R), the value leader of professional tax preparation and filing solutions, has released its 2014 federal software for 1040, 1065, 1120S, 1120 and 1041 returns. All TaxACT 2014 Preparer's Editions offer tools for organization, year-end tax planning and return preparation.
BCOR: 14.00 (+0.39)

Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
CPL: 14.99 (+0.43), EBIX: 16.02 (+0.07), AVH: 13.48 (+0.19), BCOR: 14.00 (+0.39), BLMN: 22.35 (+0.53)

Blucora Announces Appointment of Mark Finkelstein as Chief Legal and Administrative Officer
Marketwire - Thu Oct 02, 7:52PM CDT
Blucora, Inc. (NASDAQ: BCOR) today announced the appointment of Mark Finkelstein as Chief Legal and Administrative Officer, effective September 30. Mr. Finkelstein will oversee the Company's legal, compliance, and human resources departments and serve as an advisor on legal and corporate strategy matters. The Company's General Counsel & Secretary and its Vice President of Human Resources will report directly to him.
BCOR: 14.00 (+0.39)

TaxACT Launches Its Free Tax Planning Solutions for 2014 Tax Returns
Marketwire - Thu Oct 02, 10:17AM CDT
TaxACT(R), the critically acclaimed leader of digital and download tax preparation solutions, has released tax year 2014 federal solutions. With all e-fileable forms, TaxACT is the only year-round DIY tax planning and preparation solution that's free for all consumers.
BCOR: 14.00 (+0.39)

Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
ACAS: 14.90 (+0.03), CHTR: 160.00 (+1.37), CPRT: 34.23 (+0.12), CRZO: 51.21 (+1.19), BCOR: 14.00 (+0.39)

Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
BWC: 30.05 (+0.01), ACAS: 14.90 (+0.03), AFOP: 12.73 (+0.39), BCOR: 14.00 (+0.39), BLMN: 22.35 (+0.53)

Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
BDE: 8.47 (-0.09), ALOG: 71.05 (-0.56), ASEI: 49.35 (+0.85), BCOR: 14.00 (+0.39), AIR: 25.51 (-0.16)

Avantax, Inc. (AVTA) Stock Research Links

AVTA Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...